Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial -

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Information type: Other primary research
Source: The Lancet
Specialities: Cardiovascular system disorders
Summary
This analysis (n=25,982) found a steady decline in risk of major cardiovascular outcomes with lower LDL cholesterol levels achieved after 4 weeks of evolocumab treatment (e.g. 8.1% for LDL-cholesterol <0.5 mmol/L v 11.9% for ≥ 2.6 mmol/L; HR 0.76, 95% CI 0.64-0.90, P<0.0001).
UKMi comment
The authors report no safety concerns with achievement of LDL-cholesterol concentrations <0.2 mmol/L and say that their findings support further LDL-cholesterol lowering in patients with cardiovascular disease to well below current recommendations.
Related links: Editorial